HealthyPhase 1NCT07275775
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
A Phase 1 study testing D-2570 in people with Healthy, run by InventisBio Co., Ltd at 1 site in China.
Trial summary
This is a randomized, double-blind, placebo-controlled single and multiple ascending dose and food effect study on PK. Subjects in the SAD and MAD study take the drug under fasting conditions, while those in the food effect (FE) study are required to take the drug under fasting or fed conditions according to the… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- D-2570
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 13 Aug 2024to 23 Jun 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subjects who voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
- Subjects who can take effective contraceptive measures from the start of screening to 6 months after the last dose of the IMP;
- Male and female subjects aged 18 to 45 years (inclusive);
- Male weight ≥ 50 kg, female weight ≥ 45 kg. Body mass index (BMI) = body weight (kg) / height2 (m2). BMI ranging from 19 to 26 kg/m2 (inclusive);
- Subjects without medical history of clinically significant respiratory, circulatory, digestive, urinary, hematological, endocrine, nervous system diseases, metabolic abnormalities or infections, etc.
Who cannot join
- More than 5 cigarettes per day on average within 3 months before screening;
- Subjects with a clinically significant history of drug allergy or specific allergic diseases (asthma, urticaria) or known allergy to the IMP or its excipients;
- History of alcohol abuse (consuming an average of 14 units of alcohol per week within 3 months prior to screening: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
- Subjects with a history of substance or drug abuse or a positive urine drug screening;
- Blood donation or massive blood loss (>450 mL) within 3 months before screening.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
This is a randomized, double-blind, placebo-controlled single and multiple ascending dose and food effect study on PK. Subjects in the SAD and MAD study take the drug under fasting conditions, while those in the food effect (FE) study are required to take the drug under fasting or fed conditions according to the protocol.
- Conditions
- Healthy
- Being tested
- D-2570, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D-2570Drug
D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain, which can inhibit the release of inflammatory factors and participate in immune regulation. D-2570 is being developed as a potential oral therapeutic drug for patients with psoriasis, ulcerative colitis, SLE, and other conditions.
PlaceboDrug
A placebo refers to a tablet that has no therapeutic effect on medication.
| Study group | Role | What they receive |
|---|---|---|
| Compare the safety and tolerability of D-2570 tablets with Placebo for evaluation | Experimental | To assess the safety and tolerability of single, multiple doses and food effect trial of D-2570 tablets and Placebo in healthy subjects. Receives: Drug: D-2570; Drug: Placebo |
| Characterize the pharmacokinetics of single, multiple doses of D-2570 tablets and Placebo | Experimental | To characterize the pharmacokinetics (PK) of single, multiple doses of D-2570 tablets and Placebo in healthy subjects. Receives: Drug: D-2570; Drug: Placebo |
| Compare the effects of D-2570 with Placebo on the QT/QTc interval for assess | Experimental | To assess the effects of D-2570 and Placebo on the QT/QTc interval in healthy subjects. Receives: Drug: D-2570; Drug: Placebo |
| Compare the effects of multiple doses D-2570 with Placebo on serum IL-17A | Experimental | To assess the effects of multiple doses D-2570 and Placebo on serum IL-17A in healthy subjects. Receives: Drug: D-2570; Drug: Placebo |
| Assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets | Experimental | To assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets. Receives: Drug: D-2570 |
| Evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) | Experimental | To evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) and D-2570 tablets (3 mg specification) Receives: Drug: D-2570 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events
Incidence of adverse events
Measured: During the procedure
Result of vital signs
Test of resting blood pressure.
Measured: During the procedure
Result of vital signs
Test of resting heart pulse.
Measured: During the procedure
Result of vital signs
Test of respiratory rate.
Measured: During the procedure
Result of vital signs
Test of body temperature.
Measured: During the procedure
Result of physical examination
Test of height (meters）
Measured: During the procedure
Result of physical examination
Test of weight (kilograms)
Measured: During the procedure
Result of electrocardiogram
Test of beats per minute
Measured: During the procedure
Result of electrocardiogram
Test of RR Interva
Measured: During the procedure
Result of electrocardiogram
Test of PR Interva
Measured: During the procedure
Result of electrocardiogram
Test of QRS Interva
Measured: During the procedure
Result of electrocardiogram
Test of QT Interva
Measured: During the procedure
Result of electrocardiogram
Test of QTcF msec
Measured: During the procedure
Result of PK endpoints
Tmax
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
Tmax
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
Tmax
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
Cmax
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
Cmax
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
Cmax
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
t1/2
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
t1/2
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
t1/2
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
MRT
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
MRT
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
MRT
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
AUC0-∞
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
AUC0-∞
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
AUC0-∞
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
AUC0-t
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
AUC0-t
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
AUC0-t
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
CL/F
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
CL/F
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
CL/F
Measured: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
Vz/F
Measured: Day1 to Day7 of group SAD
Result of PK endpoints
Vz/F
Measured: Day1 to Day13 of group MAD
Result of PK endpoints
Vz/F
Measured: Day1 to Day7 for every cycle of group FE
Assessment of hematology test
Red blood cell count
Measured: During the procedure
Assessment of hematology test
Hemoglobin measurement
Measured: During the procedure
Assessment of hematology test
Hematocrit measurement
Measured: During the procedure
Assessment of hematology test
Platelet count
Measured: During the procedure
Assessment of hematology test
White blood cell count
Measured: During the procedure
Assessment of hematology test
Lymphocyte count
Measured: During the procedure
Assessment of hematology test
Neutrophil count
Measured: During the procedure
Assessment of hematology test
Monocyte count
Measured: During the procedure
Assessment of hematology test
Eosinophil count
Measured: During the procedure
Assessment of hematology test
Basophil count
Measured: During the procedure
Assessment of urinalysis test
pH measurement
Measured: During the procedure
Assessment of urinalysis test
Protein detection
Measured: During the procedure
Assessment of urinalysis test
White blood cells count
Measured: During the procedure
Assessment of urinalysis test
Red blood cells count
Measured: During the procedure
Assessment of urinalysis test
Glucose measurement
Measured: During the procedure
Assessment of urinalysis test
Specific gravity measurement
Measured: During the procedure
Assessment of coagulation parameters test
Thrombin time
Measured: During the procedure
Assessment of coagulation parameters test
Partial thromboplastin time
Measured: During the procedure
Assessment of coagulation parameters test
International normalized ratio
Measured: During the procedure
Assessment of coagulation parameters test
Fibrinogen
Measured: During the procedure
Assessment of blood biochemistry test
Sodium
Measured: During the procedure
Assessment of blood biochemistry test
Potassium
Measured: During the procedure
Assessment of blood biochemistry test
Calcium
Measured: During the procedure
Assessment of blood biochemistry test
Chlorine
Measured: During the procedure
Assessment of blood biochemistry test
Total protein
Measured: During the procedure
Assessment of blood biochemistry test
Albumin
Measured: During the procedure
Assessment of blood biochemistry test
Alkaline phosphatase
Measured: During the procedure
Assessment of blood biochemistry test
Alanine aminotransferase
Measured: During the procedure
Assessment of blood biochemistry test
Aspartate aminotransferase
Measured: During the procedure
Assessment of blood biochemistry test
Direct bilirubin
Measured: During the procedure
Assessment of blood biochemistry test
Indirect bilirubin
Measured: During the procedure
Assessment of blood biochemistry test
Total bilirubin
Measured: During the procedure
Assessment of blood biochemistry test
Gamma glutamyl transferase
Measured: During the procedure
Assessment of blood biochemistry test
Uric acid
Measured: During the procedure
Assessment of blood biochemistry test
Creatinine
Measured: During the procedure
Assessment of blood biochemistry test
Creatine kinase
Measured: During the procedure
Assessment of blood biochemistry test
Urea
Measured: During the procedure
Assessment of blood biochemistry test
Glucose
Measured: During the procedure
Assessment of blood biochemistry test
Total cholesterol
Measured: During the procedure
Assessment of blood biochemistry test
Triglycerides
Measured: During the procedure
Secondary outcomes (4)
Result of safety endpoint
Test of QT Interva.
Measured: During the procedure
Result of safety endpoint
Test of QTc Interva.
Measured: During the procedure
Result of PD endpoint
Test of serum IL-17A.
Measured: Day1 of group SAD
Result of PD endpoint
Test of serum IL-17A.
Measured: Day1 and Day7 of group MAD
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2025
- Study start13 Aug 2024
- Primary completion23 Jun 2025
- Study completion23 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by InventisBio Co., LtdThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- InventisBio Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07275775
- Sponsor's protocol ID
- D2570-102
- Status last verified
- Jun 2025
- First submitted
- 4 Nov 2024
- Last updated
- 10 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
- ClinicalTrials.gov ID
- NCT07275775
- Acronym / sponsor ID
- D2570-102
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- InventisBio Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 13 Aug 2024 (actual)
- Primary completion
- 23 Jun 2025 (actual)
- Study completion
- 23 Jun 2025 (actual)
- First posted
- 10 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind, placebo-controlled single and multiple ascending dose and food effect study on PK. Subjects in the SAD and MAD study take the drug under fasting conditions, while those in the food effect (FE) study are required to take the drug under fasting or fed conditions according to the protocol.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Compare the safety and tolerability of D-2570 tablets with Placebo for evaluation | Experimental | Drug: D-2570, Drug: PlaceboTo assess the safety and tolerability of single, multiple doses and food effect trial of D-2570 tablets and Placebo in healthy subjects. |
| Characterize the pharmacokinetics of single, multiple doses of D-2570 tablets and Placebo | Experimental | Drug: D-2570, Drug: PlaceboTo characterize the pharmacokinetics (PK) of single, multiple doses of D-2570 tablets and Placebo in healthy subjects. |
| Compare the effects of D-2570 with Placebo on the QT/QTc interval for assess | Experimental | Drug: D-2570, Drug: PlaceboTo assess the effects of D-2570 and Placebo on the QT/QTc interval in healthy subjects. |
| Compare the effects of multiple doses D-2570 with Placebo on serum IL-17A | Experimental | Drug: D-2570, Drug: PlaceboTo assess the effects of multiple doses D-2570 and Placebo on serum IL-17A in healthy subjects. |
| Assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets | Experimental | Drug: D-2570To assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets. |
| Evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) | Experimental | Drug: D-2570To evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) and D-2570 tablets (3 mg specification) |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Subjects who voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
- Subjects who can take effective contraceptive measures from the start of screening to 6 months after the last dose of the IMP;
- Male and female subjects aged 18 to 45 years (inclusive);
- Male weight ≥ 50 kg, female weight ≥ 45 kg. Body mass index (BMI) = body weight (kg) / height2 (m2). BMI ranging from 19 to 26 kg/m2 (inclusive);
- Subjects without medical history of clinically significant respiratory, circulatory, digestive, urinary, hematological, endocrine, nervous system diseases, metabolic abnormalities or infections, etc.
Key exclusion criteria (5 listed)
- More than 5 cigarettes per day on average within 3 months before screening;
- Subjects with a clinically significant history of drug allergy or specific allergic diseases (asthma, urticaria) or known allergy to the IMP or its excipients;
- History of alcohol abuse (consuming an average of 14 units of alcohol per week within 3 months prior to screening: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
- Subjects with a history of substance or drug abuse or a positive urine drug screening;
- Blood donation or massive blood loss (>450 mL) within 3 months before screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D-2570D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain, which can inhibit the release of inflammatory factors and participate in immune regulation. D-2570 is being developed as a potential oral therapeutic drug for patients with psoriasis, ulcerative colitis, SLE, and other conditions. | Drug | Assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets, Characterize the pharmacokinetics of single, multiple doses of D-2570 tablets and Placebo, Compare the effects of D-2570 with Placebo on the QT/QTc interval for assess, Compare the effects of multiple doses D-2570 with Placebo on serum IL-17A, Compare the safety and tolerability of D-2570 tablets with Placebo for evaluation, Evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) |
| PlaceboA placebo refers to a tablet that has no therapeutic effect on medication. | Drug | Characterize the pharmacokinetics of single, multiple doses of D-2570 tablets and Placebo, Compare the effects of D-2570 with Placebo on the QT/QTc interval for assess, Compare the effects of multiple doses D-2570 with Placebo on serum IL-17A, Compare the safety and tolerability of D-2570 tablets with Placebo for evaluation |
Primary outcome
Incidence of adverse events
Time frame: During the procedure
Incidence of adverse events
Result of vital signs
Time frame: During the procedure
Test of resting blood pressure.
Result of vital signs
Time frame: During the procedure
Test of resting heart pulse.
Result of vital signs
Time frame: During the procedure
Test of respiratory rate.
Result of vital signs
Time frame: During the procedure
Test of body temperature.
Result of physical examination
Time frame: During the procedure
Test of height (meters）
Result of physical examination
Time frame: During the procedure
Test of weight (kilograms)
Result of electrocardiogram
Time frame: During the procedure
Test of beats per minute
Result of electrocardiogram
Time frame: During the procedure
Test of RR Interva
Result of electrocardiogram
Time frame: During the procedure
Test of PR Interva
Result of electrocardiogram
Time frame: During the procedure
Test of QRS Interva
Result of electrocardiogram
Time frame: During the procedure
Test of QT Interva
Result of electrocardiogram
Time frame: During the procedure
Test of QTcF msec
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
Tmax
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
Tmax
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
Tmax
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
Cmax
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
Cmax
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
Cmax
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
t1/2
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
t1/2
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
t1/2
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
MRT
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
MRT
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
MRT
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
AUC0-∞
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
AUC0-∞
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
AUC0-∞
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
AUC0-t
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
AUC0-t
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
AUC0-t
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
CL/F
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
CL/F
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
CL/F
Result of PK endpoints
Time frame: Day1 to Day7 of group SAD
Vz/F
Result of PK endpoints
Time frame: Day1 to Day13 of group MAD
Vz/F
Result of PK endpoints
Time frame: Day1 to Day7 for every cycle of group FE
Vz/F
Assessment of hematology test
Time frame: During the procedure
Red blood cell count
Assessment of hematology test
Time frame: During the procedure
Hemoglobin measurement
Assessment of hematology test
Time frame: During the procedure
Hematocrit measurement
Assessment of hematology test
Time frame: During the procedure
Platelet count
Assessment of hematology test
Time frame: During the procedure
White blood cell count
Assessment of hematology test
Time frame: During the procedure
Lymphocyte count
Assessment of hematology test
Time frame: During the procedure
Neutrophil count
Assessment of hematology test
Time frame: During the procedure
Monocyte count
Assessment of hematology test
Time frame: During the procedure
Eosinophil count
Assessment of hematology test
Time frame: During the procedure
Basophil count
Assessment of urinalysis test
Time frame: During the procedure
pH measurement
Assessment of urinalysis test
Time frame: During the procedure
Protein detection
Assessment of urinalysis test
Time frame: During the procedure
White blood cells count
Assessment of urinalysis test
Time frame: During the procedure
Red blood cells count
Assessment of urinalysis test
Time frame: During the procedure
Glucose measurement
Assessment of urinalysis test
Time frame: During the procedure
Specific gravity measurement
Assessment of coagulation parameters test
Time frame: During the procedure
Thrombin time
Assessment of coagulation parameters test
Time frame: During the procedure
Partial thromboplastin time
Assessment of coagulation parameters test
Time frame: During the procedure
International normalized ratio
Assessment of coagulation parameters test
Time frame: During the procedure
Fibrinogen
Assessment of blood biochemistry test
Time frame: During the procedure
Sodium
Assessment of blood biochemistry test
Time frame: During the procedure
Potassium
Assessment of blood biochemistry test
Time frame: During the procedure
Calcium
Assessment of blood biochemistry test
Time frame: During the procedure
Chlorine
Assessment of blood biochemistry test
Time frame: During the procedure
Total protein
Assessment of blood biochemistry test
Time frame: During the procedure
Albumin
Assessment of blood biochemistry test
Time frame: During the procedure
Alkaline phosphatase
Assessment of blood biochemistry test
Time frame: During the procedure
Alanine aminotransferase
Assessment of blood biochemistry test
Time frame: During the procedure
Aspartate aminotransferase
Assessment of blood biochemistry test
Time frame: During the procedure
Direct bilirubin
Assessment of blood biochemistry test
Time frame: During the procedure
Indirect bilirubin
Assessment of blood biochemistry test
Time frame: During the procedure
Total bilirubin
Assessment of blood biochemistry test
Time frame: During the procedure
Gamma glutamyl transferase
Assessment of blood biochemistry test
Time frame: During the procedure
Uric acid
Assessment of blood biochemistry test
Time frame: During the procedure
Creatinine
Assessment of blood biochemistry test
Time frame: During the procedure
Creatine kinase
Assessment of blood biochemistry test
Time frame: During the procedure
Urea
Assessment of blood biochemistry test
Time frame: During the procedure
Glucose
Assessment of blood biochemistry test
Time frame: During the procedure
Total cholesterol
Assessment of blood biochemistry test
Time frame: During the procedure
Triglycerides
4 secondary outcomes
Result of safety endpoint
Time frame: During the procedure
Result of safety endpoint
Time frame: During the procedure
Result of PD endpoint
Time frame: Day1 of group SAD
Result of PD endpoint
Time frame: Day1 and Day7 of group MAD
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Active, not recruitingPhase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Pneumococcal Disease
Recruiting
Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints
Digestive Health, Quality of Life
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing D-2570 in people with Healthy, run by InventisBio Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events (time frame: During the procedure). The study lists 77 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.